

Status: Currently Official on 16-Feb-2025  
Official Date: Official as of 01-Aug-2017  
Document Type: USP Monographs  
DocId: GUID-67CB7C1F-FCFB-42B0-81D3-6CA793483D91\_1\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M56120\\_01\\_01](https://doi.org/10.31003/USPNF_M56120_01_01)  
DOI Ref: 8vx02

© 2025 USPC  
Do not distribute

# Neomycin and Polymyxin B Sulfates and Bacitracin Ophthalmic Ointment

## DEFINITION

Neomycin and Polymyxin B Sulfates and Bacitracin Ophthalmic Ointment is a sterile ointment containing Neomycin Sulfate, Polymyxin B Sulfate, and Bacitracin. It contains the equivalent of NLT 90.0% and NMT 140.0% of the labeled amounts of neomycin, polymyxin B, and bacitracin.

## IDENTIFICATION

- **A. [THIN-LAYER CHROMATOGRAPHIC IDENTIFICATION TEST \(201BNP\)](#):** Meets the requirements

## ASSAY

### • NEOMYCIN

(See [Antibiotics—Microbial Assays \(81\)](#).)

**Sample solution:** Shake a portion of Ophthalmic Ointment in a separator with 50 mL of [ether](#). Extract with four 20-mL portions of *Buffer B.3*. Combine the aqueous extracts, and dilute with *Buffer B.3* to a suitable volume.

**Analysis:** Proceed as directed in the chapter. Dilute the *Sample solution* with *Buffer B.3* to obtain a *Test Dilution* having a neomycin concentration that is nominally equivalent to the median level of the standard.

**Acceptance criteria:** 90.0%–140.0%

### • POLYMYXIN B

(See [Antibiotics—Microbial Assays \(81\)](#).)

**Sample solution:** Shake a portion of Ophthalmic Ointment with 50 mL of [ether](#) in a separator. Extract with four 25-mL portions of *Buffer B.6*. Combine the aqueous extracts, and dilute with *Buffer B.6* to a suitable volume.

**Analysis:** Proceed as directed in the chapter. Dilute the *Sample solution* with *Buffer B.6* to obtain a *Test Dilution* having a concentration that is nominally equivalent to the median level of the standard (10 Polymyxin B Units/mL). Add to each *Test Dilution* of the standard, a quantity of [USP Neomycin Sulfate RS](#), dissolved in *Buffer B.6*, to obtain the same concentration of neomycin as in the *Test Dilution* of the sample.

**Acceptance criteria:** 90.0%–140.0%

### • BACITRACIN

(See [Antibiotics—Microbial Assays \(81\)](#).)

**Sample solution:** Shake a portion of Ophthalmic Ointment with 50 mL of [ether](#) in a separator. Extract with four 25-mL portions of [0.01 N hydrochloric acid](#). Combine the acid extracts, and dilute with [0.01 N hydrochloric acid](#) to a suitable volume.

**Analysis:** Proceed as directed in the chapter. Dilute the *Sample solution* with *Buffer B.1* to obtain a *Test Dilution* having a concentration that is nominally equivalent to the median level of the standard (1.0 Bacitracin Unit/mL). If the *Sample solution* has a concentration of less than 100 Bacitracin Units/mL, add hydrochloric acid to each *Test Dilution* of the standard to obtain the same concentration of hydrochloric acid as in the *Test Dilution* of the sample.

**Acceptance criteria:** 90.0%–140.0%

## SPECIFIC TESTS

- **[STERILITY TESTS \(71\)](#):** Meets the requirements
- **OTHER REQUIREMENTS:** It meets the requirements for *Particulate and Foreign Matter* and *Container Contents* in [Ophthalmic Products—Quality Tests \(771\)](#), *Drug Product Quality, Universal Tests, Particulate and Foreign Matter* and [Container Contents](#).

## ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in collapsible ophthalmic ointment tubes.
- **[USP REFERENCE STANDARDS \(11\)](#):**
  - [USP Bacitracin Zinc RS](#)
  - [USP Neomycin Sulfate RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN OPHTHALMIC OINTMENT	<a href="#">Julie Zhang</a> Associate Science & Standards Liaison	BIO42020 Biologics Monographs 4 - Antibiotics
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	BIO42020 Biologics Monographs 4 - Antibiotics

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 39(5)

**Current DocID:** GUID-67CB7C1F-FCFB-42B0-81D3-6CA793483D91\_1\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M56120\\_01\\_01](https://doi.org/10.31003/USPNF_M56120_01_01)

**DOI ref:** [8vx02](#)

OFFICIAL